Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

Blood

Volumn 114, Issue 18, 2009, Pages 3909-3916

  Le Dieu, Rifca ^a   Taussig, David C ^a   Ramsay, Alan G ^a   Mitter, Richard ^b   Miraki Moud, Faridah ^a   Fatah, Rewas ^a   Lee, Abigail M ^a   Andrew Lister, T ^a   Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD3 ANTIGEN; CD56 ANTIGEN; PHOSPHOTYROSINE; CD36 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; BLAST CELL CRISIS; BLOOD; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD36; BLAST CRISIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENOTYPE; HUMANS; IMMUNOLOGICAL SYNAPSES; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 70449711157     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-206946     Document Type: Article

References (33)

1. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562.
2. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-129.
3. Levy R, Robertson M, Leonard J, Vose J, Denney D. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (ID) conjugated to KLH (ID-KLH) with GM-CSF compared to non-specific immunotherapy, KLH with GM-CSF in patients with follicular non-Hodgkin's lymphoma [abstract]. Ann Oncol. 2008;19(suppl 4). Abstract 057.
4. Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797-1805.
5. Görgün G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A. 2009;106(15):6250-6255.
6. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol. 2000;1(1): 23-29.
7. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
8. Behl D, Porrata LF, Markovic SN, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 2006;20(1):29-34.
9. Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002;16(7):1311-1318.
10. Bruserud O. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells. Cancer Immunol Immunother. 1998b;46(4):221-228.
11. Wendelbo O, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud O. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother. 2004; 53(8):740-747.
12. Bruserud O, Ulvestad E, Berentsen S, Bergheim J, Nesthus I. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation. Scand J Immunol. 1998a; 47(1):54-62.
13. Lim SH, Worman CP, Jewell AP, Goldstone AH. Cellular cytotoxic function and potential in acute myelogenous leukaemia. Leuk Res. 1991;15(7): 641-644.
14. Buggins AG, Milojkovic D, Arno MJ, et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol. 2001;167(10):6021-6030.
15. Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function-implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol. 2001;126(3):403-411.
16. Milojkovic D, Devereux S, Westwood NB, Mufti GJ, Thomas NS, Buggins AG. Antiapoptotic microenvironment of acute myeloid leukemia. J Immunol. 2004;173(11):6745-6752.
17. Vidriales MB, Orfao A, Lopez-Berges MC, et al. Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution. Ann Hematol. 1993; 67(5):217-222.
18. Panoskaltsis N, Reid CD, Knight SC. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia. 2003;17(4):716-730.
19. Le Dieu R, Taussig D, Lister TA, Gribben JG. Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. J Immunol Methods. 2009;348(1-2):95-100.
20. National Center for Biotechnology Information. PubMed. http://www.ncbi.nlm.nih.gov/pubmed. Accessed September 22, 2009.
21. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www.ncbi. nlm.nih.gov/geo. Accessed September 22, 2009.
22. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-210.
23. National Center for Biotechnology Information. Gene Expression Omnibus Series accession number GSE14924. http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?acc = GSE14924. Accessed August 4, 2009.
24. Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med. 1997;186(9): 1407-1418.
25. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today. 1999;20(4):177-180.
26. Wang M, Windgassen D, Papoutsakis ET. Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics. 2008;9:225.
27. Domínguez-Villar M, Munoz-Suano A, Anaya-Baz B, et al. Hepatitis C virus core protein up-regulates anergy-related genes and a new set of genes, which affects T cell homeostasis. J Leukoc Biol. 2007;82(5):1301-1310.
28. Ersvaer E, Hampson P, Wendelbo O, Lord JM, Gjertsen BT, Bruserud O. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 2007;12(3):199-207.
29. Lemster BH, Michel JJ, Montag DT, et al. Induction of CD56 and TCR-independent activation of T cells with aging. J Immunol. 2008;180(3):1979-1990.
30. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004;114(10):1379-1388.
31. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000;164(3):1148-1152.
32. Ohkawa T, Seki S, Dobashi H, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology. 2001;103(3):281-290.
33. Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009;113(5): 1002-1005.